A Randomized Double-blind, Placebo-controlled Single and Multiple Intravenous Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of GATE-101 in Normal Healthy Volunteers
Latest Information Update: 09 Aug 2022
Price :
$35 *
At a glance
- Drugs GATE 101 (Primary)
- Indications Hypersomnia; Major depressive disorder
- Focus Adverse reactions
- Sponsors Gate Neurosciences
- 01 Aug 2022 Status changed from recruiting to discontinued.
- 26 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.
- 26 Jul 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Oct 2021.